Cancer Discov. 2014 Feb;4(2):OF6. doi: 10.1158/2159-8290.CD-NB2013-157. Epub 2013 Nov 14.
The National Cancer Institute has released a 30-item checklist to evaluate the readiness of complex omics-based tests used to guide therapeutic choices for patients in a clinical trial. The checklist pertains to tests that combine multiple molecular measures from genomic, proteomic, metabolomic, transcriptomic, epigenomic, or other omics assays into predictive mathematical models. The agency will approve tests for use in a trial only if all 30 criteria have been adequately addressed.
美国国家癌症研究所发布了一份 30 项清单，用于评估用于指导临床试验中患者治疗选择的复杂基于组学的测试的准备情况。该清单涉及将来自基因组学、蛋白质组学、代谢组学、转录组学、表观基因组学或其他组学分析的多个分子测量值组合到预测性数学模型中的测试。只有在所有 30 项标准都得到充分解决的情况下，该机构才会批准在试验中使用这些测试。
